Alnylam Pharmaceuticals
Scientist, Quality Control Microbiology (Finance)
Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including five programs in late-stage development. Alnylam currently has two commercial RNAi therapeutic products. The first product is approved in the U.S., EU, Canada, Japan, and Switzerland for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults and the second product is approved in the U.S. for the treatment of adults with acute hepatic porphyria (AHP). Alnylam also has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Headquartered in Cambridge, Mass., Alnylam employs over 1,300 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work five years in a row (2015-2019), a Great Place to Work in the U.K. and Switzerland in 2019 and Science Magazine's #1 Top Employer in 2019. Please visit www.alnylam.com for more information.
The Quality Control Microbiology Scientist will be primarily responsible for oversight of environmental monitoring (EM) and critical utility (CU) trend reports, excursion investigations and facility and equipment qualification in support of our new GMP manufacturing at the Alnylam - Norton facility, 20 Commerce Way, Norton, MA and supporting the Alewife facility, 665 Concord Avenue, Cambridge, MA. The position requires flexibility with changing priorities.
Summary of Key Responsibilities